Perrigo Company plc Loss Contingency, Receivable, Additions
Perrigo Company plc (PRGO) reported Loss Contingency, Receivable, Additions of $28.70 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency › Loss Contingency, Related Receivable
us-gaap:LossContingencyRelatedReceivableCarryingValueAdditions · last filed 2024-02-27
- Perrigo Company plc loss contingency, receivable, additions for the quarter ending 2023-07-01 was -$2.00M.
- Perrigo Company plc loss contingency, receivable, additions for the quarter ending 2023-04-01 was $37.20M, a 18.95% decline year-over-year.
- Perrigo Company plc loss contingency, receivable, additions for the quarter ending 2022-12-31 was -$4.40M.
- Perrigo Company plc loss contingency, receivable, additions for the quarter ending 2022-10-01 was -$700.00K.
- Perrigo Company plc loss contingency, receivable, additions for fiscal 2023 was $28.70M, a 25.26% decline from fiscal 2022.
- Perrigo Company plc loss contingency, receivable, additions for fiscal 2022 was $38.40M, a 51.39% decline from fiscal 2021.
- Perrigo Company plc loss contingency, receivable, additions for fiscal 2021 was $79.00M.
| Period end | Loss Contingency, Receivable, Additions 3 month | Loss Contingency, Receivable, Additions 6 month | Loss Contingency, Receivable, Additions 9 month | Loss Contingency, Receivable, Additions 12 month |
|---|---|---|---|---|
| 2023-12-31 | $28.70M 10-K · filed 2024-02-27 | |||
| 2023-07-01 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $35.20M 10-Q · filed 2023-08-08 | $30.80M derived: sum of 3 quarters · filed 2023-08-08 | $30.10M derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-04-01 | $37.20M 10-Q · filed 2023-05-09 | $32.80M derived: sum of 2 quarters · filed 2023-05-09 | $32.10M derived: sum of 3 quarters · filed 2023-05-09 | $29.70M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | -$4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$5.10M derived: sum of 2 quarters · filed 2023-02-28 | -$7.50M derived: sum of 3 quarters · filed 2023-02-28 | $38.40M 10-K · filed 2023-02-28 |
| 2022-10-01 | -$700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$3.10M derived: sum of 2 quarters · filed 2022-11-08 | $42.80M 10-Q · filed 2022-11-08 | |
| 2022-07-02 | -$2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $43.50M 10-Q · filed 2022-08-09 | ||
| 2022-04-02 | $45.90M 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $79.00M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |